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The fate of intraperitoneally injected or implanted male rat bone marrow-derived stromal cells inside female sibling host animals
was traced using Y-chromosome-sensitive PCR. When injected intraperitoneally, Y-chromosome-positive cells were found in all
studiedorgans:heartmuscle,lung,thymus,liver,spleen,kidney,skin,andfemoralbonemarrowwithafewexceptionsregardlessof
whethertheyhadgonethroughosteogenicdiﬀerentiationornot.Intheimplantexperiments,expandeddonorcellswereseededon
poly(lactide-co-glycolide) scaﬀolds and grown under three diﬀerent conditions (no additives, in osteogenic media for one or two
weeks) prior to implantation into corticomedullar femoral defects. Although the impact of osteogenic in vitro cell diﬀerentiation
on cell migration was more obvious in the implantation experiments than in the intraperitoneal experiments, the donor cells stay
alive when injected intraperitoneally or grown in an implant and migrate inside the host. However, when the implants contained
bioactive glass, no signs of Y-chromosomal DNA were observed in all studied organs including the implants indicating that the
cells had been eliminated.
1.Introduction
Tissue engineering is a relatively new ﬁeld of medicine that
has been hoped to provide assistance in treating failing
tissues and organs [1]. Although many of the practical
issues are still unsolved, using the patient’s own stem cells
in combination with suitable tissue engineering scaﬀolds
[2] removes all the immunological complications of using
allografts and can, at least in theory, provide an unlimited
source of, for example, bone tissue [2, 3].
Evidence that bone marrow contains cells that can
diﬀerentiate into mesenchymal cells started with the work
of Friedenstein and coworkers [4, 5] .T h e s eb o n em a r r o w -
derived stromalcells (BMSCs)were latershown tohave bone
forming capabilities when grown under certain conditions
[6] as well as chondrogenic and adipogenic properties [7].
BMSCs, including human, have been shown to retain
their activity after intraperitoneal injection [8]. There are
also compelling indications that injected BMSCs can circu-
late in the body and home in on target tissues [8, 9]. In this
study, we aimed to test whether the degree of osteogenic in
vitro diﬀerentiation of the bone marrow-derived donor cells
aﬀected the fate of the cells when infused into the peritoneal
cavity of rats.
Less is known about what happens to the donor cells
inside the hostbody whenimplanted into bone defects.Bone
is a highly vascular tissue [10], and therefore it is extremely
plausible that implanted cells leave the defect area and2 Journal of Tissue Engineering
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Figure 1: Flow chart illustrating the diﬀerent phases and the setup of the implant and intraperitoneal experiments.
migrate to other organs of the host. While this might cause
unique risks for tissue engineering, it also creates unique
opportunities for stem cell therapy, and for this reason we
traced the implanted cells to ﬁnd out if they migrated to
other organs outside the defect area.
Poly(dl-lactide-co-glycolide) (PLGA) was chosen as the
scaﬀold material for the seeding of cells. PLGA is a porous
biodegradable copolymer based on synthetic aliphatic
polyesters and is used in several medical applications [11]. It
can be synthesized to achieve speciﬁc physical and chemical
characteristics. PLGA has also been shown to be a suitable
material for seeding cells [10]. As the material characteristics
can be further improved by composite preparation with
bioceramics [12], we also tested the impact of bioactive glass
(BAG) in the PLGA scaﬀolds on the behavior of the donor
cells inside the host animals.
2.MaterialsandMethods
2.1. Study Design. The fate of implanted BMSCs was studied
by isolating cells from male rat’s femurs and tibias, implant-
ing these cells into their female siblings by intraperitoneal
injection or femoral implantation within porous PLGA
scaﬀolds, and detecting them from isolated host tissues with
Y-chromosome-sensitive PCR (Figure 1).
2.2. Experimental Animals. For the intraperitoneal experi-
ment, 18 female Sprague Dawley rats weighing about 200g
were used. For the implantation experiments, 15 one-year-
old female Sprague Dawley rats weighing at least 300g
were used. The rats were housed individually in their cages
with free access to food pellets and drinking water. The
animal facilities are managed according to the European
ConventionfortheProtectionofVertebrateAnimalsusedfor
Experimental and Other Scientiﬁc Purposes and inspected
for GLP Compliance. The study design was approved by the
Animals Ethical Committee of the State Provincial Oﬃce of
Southern Finland.
2.3. Preparation of Porous PLGA and PLGA/BAG Composites.
PLGA 90/10 and PLGA/BAG 90/10 (20wt-%) composites
were made by solvent casting using dichloromethane (DCM)
as a solvent. Polar composites were made as follows. A
uniform layer of BAG (20wt%) was applied on the bottom
of a Teﬂon-coated form. PLGA/DCM solution (25w/v%
(g/ml)) was poured onto the BAG layer. The solvent was
ﬁrst slowly evaporated (4◦C; 1 week) after which the forms
were placed in a fume cupboard at room temperature
(48h). A similar process was used for the preparation
of composites with a homogenous structure. PLGA/DCM
solution (25w/v%) containing 20wt% BAG was poured into
a Teﬂon-coated form and stirred until most of the solvent
was evaporated. The remaining solvent was ﬁrst slowly
evaporated (4◦C; 3 days) after which the composites were
placed in a fume cupboard at room temperature (48h). The
prepared ﬁlms were stored in a desiccator until further use.
Films were processed into porous scaﬀolds by gas foaming
with high-pressure CO2 in an autoclave (50 bars) for 1h
after which the gas was rapidly released from the vessel (5s).
The porous composite ﬁlms were stored under nitrogen in a
desiccator(RT)priortouse.This methodhasbeendescribed
in detail in previous work [13].
2.4. Cell Isolation and Culture. For cell isolation, two eight-
week-old male rats were killed by cervical dislocation under
CO2 anesthesia. The femurs and tibias were dissected andJournal of Tissue Engineering 3
Table 1: Diﬀerentiation protocols used in the intraperitoneal experiment.
Intraperitoneal MSC diﬀerentiation Implantation time
Group I, IV Expansion culture only
Group II, V I week in α-MEM + 1 week in osteogenic media I–III: one week, IV–VI: two weeks
Group III, VI 2 weeks in osteogenic media, 2nd week w/o dexa
Table 2: Diﬀerentiation protocols and materials used in the implant experiments.
Implant I Material MSC diﬀerentiation
Group I PLGA 2 weeks in plain medium
Group II PLGA 1 week in α-MEM + 1 week in osteogenic media
Group III PLGA 2 weeks in osteogenic media, 2nd week w/o dexa
Implant II
Group I PLGA 2 weeks in osteogenic media, 2nd week w/o dexa
Group II PLGA + BAG 2 weeks in osteogenic media, 2nd week w/o dexa
sterilized by dipping into 70% ethanol and put into sterile
phosphate buﬀered saline (PBS). In sterile conditions, both
ends of the bone were cut oﬀ and the cells were ﬂushed
out with alpha-minimum essential medium (α-MEM) con-
taining antibiotics using a syringe and an 18G needle. The
cell suspension was centrifuged and resuspended in α-MEM
containing antibiotics (100 units/ml penicillin and 100g/ml
streptomycin) and 20% fetal calf serum (FCS).
Marrow stromal cells can be isolated from other cells in
the marrow by their tendency to adhere to plastic surfaces.
After2days,theﬂoatingcellswereremovedandtheadherent
cells were allowed to proliferate for another 5 days in a
humidiﬁedincubatorat37
◦Cand5%CO2.Themediumwas
changed twice a week.
2.5. Intraperitoneal Experiment. After the cell culture expan-
sion period of 7 days, the cells were trypsinized and cultured
according to three diﬀerent protocols (106 cells/culturing
condition). The cells were grown in proliferation medium
(α-MEM with 100 units/ml penicillin and 100g/ml strep-
tomycin and 20% FCS) for two weeks, in proliferation
mediumforoneweekandthengivenosteogenicmedium(α-
MEM, antibiotics, 20% FCS, 50g/ml ascorbic acid, 10mM
β-glycerophosphate, and 10nM dexamethasone) during the
second week, or in osteogenic medium for two weeks with
dexamethasone present only during the ﬁrst week. Dex-
amethasone was omitted the second week as this synthetic
glucocorticoid has been reported to inhibit preostoblastic
cells into terminal osteoblasts [14, 15].
Trypsinized expanded or diﬀerentiated BMSCs (Table 1)
were suspended into Hanks-buﬀer (100000 cells/ml) and 1
ml of the cell suspension was injected intraperitoneally into
the right lower abdomen of 18 female siblings of the cell
donor rats. The rats were killed 1 or 2 weeks after injection
and the samples of lung, spleen, liver, thymus, and bone
marrow from the femur were collected for DNA extraction.
2.6. Cell Seeding and Femoral Implantation Experiments.
Afterthecellcultureexpansionperiodof7days,twoseparate
implant experiments were conducted (Table 2) .P r i o rt oc e l l
seeding, the polymer discs, 10mm in diameter and 2.5mm
in thickness were sterilized in 70% ethanol for 1h and then
washed twice with sterile PBS. The discs were then incubated
over night in α-MEM without serum at 37
◦C and put into 24
well plates.
To study the impact of in vitro cell diﬀerentiation on
migration in the host animal (implant experiment I), 50000
expanded cells were seeded on 90/10 PLGA implants without
BAG. After seeding, three diﬀerent protocols were used
for cell proliferation and diﬀerentiation. In group I, the
seeded cells were kept in proliferation medium, α-MEM
with 100 units/ml penicillin and 100g/ml streptomycin
and 20% FCS for two weeks. In group II, the cells were
grown in proliferation medium for one week and then
given osteogenic medium (α-MEM, antibiotics, 20% FCS,
50g/mlascorbicacid,10mMβ-glycerophosphateand10nM
dexamethasone) during the second week. In group III, the
cells were grown in osteogenic medium for two weeks with
dexamethasone present only during the ﬁrst week.
After two weeks, the seeded implants were either stained
for alkaline phosphatase using p-nitrophenol as a substrate
(Sigma; Kit 86-r) or implanted into rat femoral bone defects
as described below.
To study the eﬀect of BAG on donor cell viability and
migration in the host animal (implant experiment II), 50000
expanded cells in a small volume (∼50μl) were seeded on
90/10 PLGA with and without 20% w-% BAG. After 3
h incubation at 37
◦C, 1ml of osteogenic growth medium
(dexamethasone present only the ﬁrst week) was added and
the cells were grown on both implant types for two weeks in
a humidiﬁed incubator at 37
◦C and 5% CO2.
2.7. Surgical Procedure for Femoral Implantation Experiments.
General anesthesia was induced by subcutaneous injection
of 0, 15–0, 2ml/100g rat weight Hypnorm (Jansen Pharma-
ceuticals, Belgium): Dormicum (Roche, Switzerland): sterile
water(1:1:2).Bonedefectsof2.4× 3 × 8mmweremade4 Journal of Tissue Engineering
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Figure 2: Presence of Y-chromosomal donor DNA in host tissues after intraperitoneal transplantation. − = negative control. In the table, +
indicates faint bands, ++ distinct bands, +/+/+ strong bands, +/− traces of, and − no bands of Y-chromosomal DNA.
with a dental drill (rose bur) in the anterolateral part of
subtrochanteric femur [16]. Each femoral implant (2.5 ×
3 × 8mm) was inserted into the left or right femur of
the rats. The polar glass composite material was inserted
with the ceramic side to the dorsolateral side. After the
operation, 100μl of buprenorphin (Temgesic, Leiras Fin-
land) was injected subcutaneously to relieve postoperative
pain.
A slower release rate of the donor cells was expected,
therefore, a four-week observation point was selected. The
animals were killed by cervical dislocation under CO2
anesthesia and the implants and the organ samples (i.e.,
opposite femur and pieces of the spleen, liver, kidney, lung,
heart, thymus and the skin from the defect area, and blood)
were collected for DNA analyses. The sample from the heart
was taken from the apex in order to get as little blood as
possible with the sample.
2.8. DNA Isolation. For DNA isolation, a 3 × 3 × 3mm
sample of tissue was cut into smaller pieces and then
digested for 16–24h at 55
◦C with Proteinase K (Finnzymes,
Finland).TheDNAwasextractedusingaphenol-chloroform
extraction protocol, where the DNA was serially extracted
from phenol, phenol-chloroform 1:1, and chloroform [17].
Between the extractions, the samples were centrifuged
(13200rpm,4min)andtheupperliquidphasewasmovedto
a new tube. The extraction product was ﬁnally treated with
30% PEG 6000/1.8M NaCl and incubated on ice for 2 hours.
The isolated DNA was then centrifuged (13200rpm, 10 min)
and washed twice with 70% ethanol and ﬁnally suspended
into TE-buﬀer. The concentration of the isolated DNA was
measured spectrophotometrically.
2.9. Detection Y-Chromosomal Marker by PCR. The iso-
lated tissue DNA was analyzed for the sex determina-
tion region on the Y-chromosome (SRY) with PCR. The
primers (forward 5 -GGCTTCAAAGTAGATTAGTTGGG-
3  and reverse 5 -ATGCATTCATGGGGCGCTTGAC-3 )
were designed according to the DNA sequence for the Rat
SRY 5  ﬂanking region (GenBank AJ 222688). Polymerase
chain reaction conditions were 94◦Cf o r5m i nf o l l o w e db y
30 cycles of 94◦C for 1 min, 61
◦Cf o r1m i n ,a n d7 2
◦Cf o r1
min.
The ﬁnal 392bp PCR products were analyzed with
electrophoresis in 1% agarose gels containing ethidium
bromide.
3. Results
3.1. Intraperitoneal Experiment. BMSCs grown in expansion
or in osteogenic media were used in the intraperitoneal
experiment (Table 1). After 1 and 2 weeks, samples from the
lung, bone marrow, thymus, liver, and spleen were collected
and analyzed for their contents of transplanted male cells by
PCR of the sex determination region on the Y-chromosome
(SRY). Regardless of cell culturing protocols, all 18 animals
that received BMSCs injected into the peritoneal cavity
were clearly positive for the Y-chromosome in the lung,
spleen, and thymus samples. The liver was positive for most
animals, in groups III and V, there was one negative animal,
respectively, and the bone marrow was also positive with
some variation in the band intensity for all animals except
o n ei ng r o u p sIa n dI I I( Figure 2).
3.2. Implant Experiments. Light microscopy examination
showed the porous structure of the scaﬀold, the proliferationJournal of Tissue Engineering 5
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Figure 3: ALP-stained BMSCs in 90/10 PLGA scaﬀold with 20w-%
BAG after 2 weeks in osteogenic media (closeups 4x magniﬁcation
stereomicroscopy image). Insert shows ALP-stained BMSCs in
PLGA and PLGA/BAG scaﬀolds after one and two weeks in
osteogenic media.
of seeded cells, and the ALP staining that is characteristic
for osteoblastic cells (Figure 3). The presence of BAG in the
scaﬀolds did not change the morphology of the implanted
cells.
PCR analyses of the ﬁrst implant experiment (see,
Table 2), where the impact of in vitro cell diﬀerentiation
on migration in the host animal was studied, revealed Y-
chromosome-positive signals in the spleen, heart, skin taken
from the wound area, and liver of all 9 animals (Figure 4).
The kidneys were negative for donor cells in all rats. In group
I (cells grown in proliferation medium only), 2/3 animals
showed positive lung samples, and 1/3 was positive when the
cells were grown in osteogenic media for two weeks before
implantation (group III). None of the lungs were positive
whenthecellswereleftinproliferationmediumforoneweek
and then cultured in osteogenic medium for an additional
week (group II), but strong positive signals were detected
in the thymuses of these animals. Also the other animals
with negative lungs, except one in group III, showed strong
positive Y-chromosome signals in the thymus and/or in the
blood.
Positive signals of the Y-chromosome were detected in all
9 implant samples. Faint signals were observed in the bone
marrow from the femur opposite the implant except for one
animal in group I.
As diﬀerentiated cells with osteoblastic morphology were
less prone to get stuck in the lungs, the cell seeding protocol
used for group III was chosen for the second implant
experiment (Table 2). In this experiment, the eﬀect of BAG
on donor cell viability and migration in the host animal
was studied as above. Positive signals for the Y-chromosome
were only found in the 90/10 PLGA implants without BAG
(Figure 5(a)) four weeks after operation. In addition, the
animals that had implants containing no BAG showed
distinctSRYbandsinthebonemarrowofthefemuropposite
the operated one, whereas the bone marrow of the animals
with PLGA/BAG implants was negative (Figure 5(b)). This
was the case for the other tissues analyzed as well (not
shown).
4. Discussion
The capacity of BMSCs to mobilize into peripheral blood
in response to trauma, such as burns and skeletal muscle
injuries, has been well documented [18, 19]. It is also known
that a small amount of BMSCs continually circulate in the
bloodstream [20].
Many studies have shown that BMSCs migrate inside the
host when injected systemically [21, 22] or intraperitoneally
[8, 23] and that they have the ability to engraft to sites of
tissue injury and inﬂammation [24]. Intravenously injected
BMSCs travel to the right side of the heart and through
there to the pulmonary artery and are mostly trapped in
the microvasculature of the lung because of their size and
the adhesion potential. BMSCs injected into the artery pass
through the tissue that the artery oxygenates and then go
into the pulmonary circulation and seem to have the same
fate of accumulating in the lungs from where they unlikely
migrate to the injury site [22]. Despite a dynamic in vivo
distribution of undiﬀerentiated BMSCs after intraperitoneal
cavity infusion in rats, considerable amount of the cells were
found lodging in the lungs as well two days after injection
[23]. This is not surprising as intraperitoneally injected
cells travel through the lymphatic circulation into the left
subclavian vein and to the right side of the heart.
Here we studied the fate of injected and implanted
undiﬀerentiated and osteogenically diﬀerentiated BMSCs
inside the host. We used the widely accepted method of
detecting Y-chromosome speciﬁc sequences by amplifying
with PCR [25, 26]. Female tissues are negative for the
Y-chromosome except if they have given birth to male
oﬀspring, when some fetal cells can hide in the female
organs [27]. In our study, the recipient rats had not been
pregnant.
Intraperitoneally infused BMSCs, regardless of the dif-
ferentiation stage, were found in lungs at both observation
time points, that is, after one and two weeks. When released
from the bone implants, less cells were trapped in the lungs,
especially diﬀerentiated cells, which are smaller in size than
the undiﬀerentiated cells. The peritoneum is highly vascular-
ized and therefore it is apparent that more cells get access to
the lymphatics and blood circulation simultaneously, which
increases the risk of getting trapped in the small capillaries
of the lungs. The slower release rate of cells escaping the
implants results in fewer cells migrating at the same time,
which probably results in less lung entrapment compared to
intraperitoneally injected cells.
Positive signals were found in the spleens of all animals,
both in the intraperitoneally injection experiments and
in the implant study without BAG. In the intraperitoneal
injection study, the livers of two animals did not give
positive signals for Y-chromosomal cells (in groups II and
V),whereasallimplantedanimalshaddonorcellsintheliver.
In previous reports [19], high numbers of transplanted cells6 Journal of Tissue Engineering
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Figure 4: Presence of Y-chromosomal donor DNA in host tissues four weeks after femoral implantation. In the implant panel, I, II, and III
are samples of the nonimplanted cell-seeded polymer. + = positive control; − = negative control. In the table, + indicates faint bands, ++
distinct bands, +/+/+ strong bands, +/− traces of, and − no bands of Y-chromosomal DNA.
have been observed in the liver and spleen. Rombouts and
Ploemacher[28]showedthattherewaslossofhomingability
of transplanted BMSCs in total body irradiated animals to
both bone marrow and spleen following culture of the cells.
However, in their study only small numbers (100 and 1000
cells) of cells were transplanted and this probably made
the detection of labeled cells diﬃcult. Following injection
of larger amounts (4 × 106) of BMSCs, both the liver and
the spleen contained histologically detectable cells one week
after transplantation [22, 29]. Our results support the theory
that the liver and spleen might serve as a secondary obstacle
for the circulating BMSCs that have passed the lung barrier.
There is, however, great controversy whether these ﬁndings
are due to homing of the cells to liver and spleen or whether
they are trapped within these organs, which belong to the
reticuloendothelial system [21, 23, 29] that functions as a
part of the immune system to remove cell debris from the
blood stream.Journal of Tissue Engineering 7
PLGA + BAG PLGA H2O
(a)
PLGA + BAG PLGA C
(b)
Figure 5: Presence of donor cells four weeks after implantation. No signals of Y-chromosomal DNA were detected in (a) the implants
containing BAG and (b) no donor cells escaped from the PGLA/BAG implants were found in the opposite femoral bone marrow. H2O =
negative control; C = positive control.
Several studies report that systematically administered
BMSCs are capable of homing to the bone marrow [30, 31]
and the thymus [32, 33]. Both are organs of lymphopoiesis,
especially in the generation of T lymphocytes. These cells are
formed in the bone marrow and migrate to the thymus to
undergo maturation. Although thymus is the primary organ
where T cell maturation happens, it has been shown that
in the absence of the thymus, the bone marrow provides
appropriate support for T cell maturation [34]. In this study,
BMSCs migrated preferentially to the thymus instead of the
bone marrow after intraperitoneal injection and femoral
implantation. Bone marrow-derived cells have been shown
to express chemokine receptors that promote migration to
the thymus [33] and to the bone marrow [29]. As the
transplanted cell circulates around the host body passing
both tissues countless times, it can be speculated that the
transplanted BMSCs express receptors that promote active
migration to the thymus in preference to bone marrow.
Thesechemokinereceptorsmightalsobeinvolvedinhoming
ofBMSCstootherlymphaticorgansingeneral,includingthe
spleen [33]. What is interesting is that even osteogenically
diﬀerentiated cells seem to have the capacity to home into
both the thymus and the bone marrow in line with the
ﬁndings of Thalmeier et al. [35], who showed that bone
marrow-derived stromal cells expressing osteogenic markers
could be detected in several recipient organs including the
thymus and bone marrow.
Three additional tissues, that is, heart, skin, and blood,
were analyzed from the animals of the bone implant
experiment. Strong signals were detected in all skin samples
taken from the wound area, indicating that the donor cells
engraftintotheinjuredskin.Itremainstobestudiedwhether
these cells participate in the wound healing process. Our
results show that seeded cells that escape from the PLGA
implants, most probably due to degradation of the scaﬀold,
were also capable to engraft into the heart as all animals
showed clearly detectable signs of donor cells in the heart
samples. Interactions between coronary artery epithelium
and BMSCs have been shown in ischemic hearts and in
animals pretreated with inﬂammatory cytokines [36], and
intravenous BMSC injection has been shown to increase left
ventricular ejection fraction of infarcted pig hearts [37]. On
the other hand, intravenously infused BMSCs do not home
t oi n t a c tm y o c a r d i u m[ 21]. What the reason is for the cells
in this study to be found in uninjured heart tissue remains
unclear.
The positive signals detected in the blood of several
animals in our implant experiment support the idea that
BMSCs can reach almost any organ via the bloodstream. It
is therefore not surprising to ﬁnd donor BMSCs in a variety
of the host’s organs, providing that these donor cells have
stayed alive, which seems to be the case for the cells in our
experiments.
Bioactive glass, however, aﬀected the outcome of the
seeded cells, but we can only speculate their fate. As no
traces of male cells were detected in these implants, it
can be assumed that all cells had escaped, “dead or alive”.
Furthermore, as no donor cells were observed in any of the
other tested tissues, the cells seemed to have been destroyed
before the tissue samples were taken for DNA analyses four
weeks after implantation or more unlikely accumulated in
diﬀerent organs than the ones tested. This negative eﬀect of
BAG on BMSCs in vivo could possibly be due to high local
alkalinity of dissolving bioactive glass [38].
5. Conclusions
In this study, we showed that in vitro cultured BMSCs can
be transplanted successfully intraperitoneally and in bone
implants and are found in a wide variety of organs after
transplantation. Femoral implantation experiments showed
that donor cells with osteoblastic morphology passed the
lung barrier and did not lose the ability to engraft the
bone marrow of the host animal. In contrast, BAG in the
PLGA seemed to have a negative eﬀect on the migration
of implanted cells. Further studies are needed to conclude
whether there is permanent engraftment of BMSCs in
diﬀerent organs and if there is, then what their contribution
to the tissue architecture is.
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